Juergen Mueller, PhDCommercial Director Nucleic Acid Therapeutics (NAT) at LGC Axolabs
Juergen is currently Commercial Director NAT (Nucleic Acid Therapeutics) at LGC Axolabs, covering the commercial and sales responsibility for all clinical service programs in the Oligo-therapeutics field within LGC. This includes worldwide marketing & sales responsibity since LGC serves clients in EU, US (North America including Canada and South America), and APAC region. Juergen spend more than >20 years in the Life Science industry while having held senior management positions in BD, Sales and Marketing, Licensing and Project Management from Fortune 500 companies, such as Sigma-Aldrich (US), up to service providers as Solvias (CH), and leading Oligo CMO’s as Nitto-Avecia (US/Jpn). Drug development experience as CSO for Syndeco (CH) while developing small molecule and peptide NCE’s from lead to clinical candidates. Author and inventor of >40 peer reviewed scientific articles and patents.